

1/9




Fig. 1

2/9




Fig. 2

3/9




Fig. 3

4/9

**The Effect of LL2-Onc vs LL2-hPanc on
Daudi Lymphoma cells**




Fig. 4

SUBSTITUTE SHEET (RULE 26)




Fig. 5A

Fig. 5B

6/9




Fig. 6

7/9

MPT Daudi/i.v. in SCID mice, 120996




Fig. 7

0098649 110700

WO 98/50435

Title: Immunotoxins, Comprising an
Internalizing Antibody, Directed
Against Malignant and Normal Cells
Inventor(s): David M. Goldenberg
DOCKET NO.: 018733-1058

PCT/US98/08983

8/9




Fig. 8

192977 6798660


WO 98/50435

Title: Immunotoxins, Comprising an
Internalizing Antibody, Directed
Against Malignant and Normal Cells
Inventor(s): David M. Goldenberg
DOCKET NO.: 018733-1058

PCT/US98/08983

9/9

Toxicity of LL2-Onc vs Onc or IT-dgRTA to Mice



RFB4-PE35KDEL, 1 x/day for 4 days: LD50 1 mg/kg
E. Mansfield et al., Bioconjugate Chem. 1996, 557

Fig. 9